|
|
Below you will find a full overview of Crucell’s R&D partners and licensees
Last update: February 9, 2009
|
|
 |
 |
  |
Preclinical |
 |
|
Phase I |
 |
|
Phase II |
 |
|
Phase III |
|
|
|
|
|
|
|
|
|
|
|
| Transgene |
|
Dec. 2007 |
|
PER.C6® |
|
Undisclosed vaccine |
|
 |
|
Merck & Co. Inc. |
|
Sep. 2007 |
|
PER.C6® + AdVac® |
|
Infectious disease areas |
|
|
|
Bestewil Holding BV |
|
Jan. 2006 |
|
Co-micelles |
|
Influenza |
|
|
|
Tibotec Pharmaceuticals Ltd |
|
Nov. 2005 |
|
PER.C6® |
|
Undisclosed vaccine |
|
|
| Okairos |
|
Oct. 2005 |
|
PER.C6® |
|
Hepatitis C |
|
|
|
Novartis |
|
Dec. 2004 |
|
PER.C6® |
|
Alphavirus vectors |
|
|
|
Vaxin, Inc. |
|
Sep. 2004 |
|
PER.C6® |
|
Alzheimers disease |
|
|
|
International AIDS Vaccine Initiative (IAVI) |
|
Sep. 2004 |
|
AdVac® |
|
HIV |
|
|
|
National Institutes of Health (NIH) |
|
Mar. 2004 |
|
PER.C6® + AdVac® |
|
Malaria |
|
|
|
Aeras Global TB Vaccine Foundation |
|
Mar. 2004 |
|
PER.C6® + AdVac® |
|
Tuberculosis |
|
|
|
Sanofi Pasteur |
|
Dec. 2003 |
|
PER.C6® |
|
Influenza |
|
|
|
Kimron Veterinary Institute |
|
July 2003 |
|
PER.C6® |
|
West Nile Virus Veterinary vaccine (avian) |
|
Marketed
in Israel |
|
Harvard School of Medicine |
|
Oct. 2002 |
|
PER.C6® + AdVac® |
|
HIV |
|
|
|
National Institutes of Health (NIH) |
|
Mar. 2002 |
|
PER.C6® + AdVac® |
|
Ebola, Lassa and Marburg |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CSL Ltd. |
|
Dec. 2008 |
|
PER.C6® |
|
Undisclosed protein |
|
|
| GlaxoSmithKline |
|
Dec. 2008 |
|
PER.C6® |
|
Recombinant
protein |
|
|
| Talecris Biotherapeutics |
|
Dec. 2008 |
|
PER.C6® |
|
Undisclosed protein |
|
|
| ProFibrix BV |
|
Dec. 2008 |
|
PER.C6® |
|
Recombinant proteins |
|
|
| Centocor |
|
Dec. 2008 |
|
PER.C6® |
|
Monoclonal antibodies |
|
|
| Synthon BV |
|
Nov. 2008 |
|
PER.C6® |
|
Biosimilar protein |
|
|
| Affitech A.S. |
|
Nov. 2008 |
|
PER.C6® |
|
Undisclosed antibodies |
|
|
| Gedeon Richter |
|
Nov. 2008 |
|
PER.C6® |
|
Undisclosed biopharmaceuticals |
|
|
| Cangene Corp. |
|
Oct. 2008 |
|
PER.C6® |
|
Undisclosed antibodies |
|
|
| Arana Therapeutics, Ltd |
|
Oct. 2008 |
|
PER.C6® |
|
Portfolio antibodies |
|
|
| Abraxis Bioscience, Inc. |
|
Oct. 2008 |
|
PER.C6® |
|
Protein production |
|
|
| Bioceros |
|
May 2008 |
|
STAR® |
|
Portfolio antibodies |
|
|
| Toyobo Gene Analysis Co. LTD. |
|
Apr. 2008 |
|
STAR® |
|
Portfolio antibodies |
|
|
| Celltrion, Inc. |
|
Apr. 2008 |
|
STAR® |
|
Portfolio antibodies |
|
|
| Medarex Inc |
|
Mar. 2008 |
|
STAR® |
|
Monoclonal antibodies |
|
|
|
MorphoSys A.G. |
|
Mar. 2008 |
|
PER.C6® |
|
Oncology |
|
|
| Medarex Inc. |
|
Dec. 2007 |
|
PER.C6® |
|
Portfolio antibodies |
|
|
|
ProFibrix |
|
Dec. 2007 |
|
STAR® |
|
Portfolio antibodies |
|
|
| Daiichi Sankyo Ltd. |
|
Nov. 2007 |
|
PER.C6® |
|
Portfolio antibodies |
|
|
| PR&D Biotech S.A. (Recepta Biopharma S.A.) |
|
Nov. 2007 |
|
PER.C6® |
|
Portfolio antibodies |
|
|
|
MedImmune |
|
Oct. 2007 |
|
PER.C6® +
MAbstract® |
|
Anti-bacterial antibodies |
|
|
| Invitrogen Corporation |
|
Sep. 2007 |
|
STAR® |
|
Monoclonal antibodies |
|
|
|
LFB Biotechnologies |
|
July 2007 |
|
PER.C6® |
|
Undisclosed antibodies |
|
|
| Masterclone |
|
July 2007 |
|
PER.C6® |
|
Undisclosed antibodies |
|
|
| Taiwanese Development Center for Biotechnology (DCB) |
|
Mar. 2007 |
|
PER.C6® |
|
Undisclosed proteins |
|
|
| Patrys |
|
Feb. 2007 |
|
PER.C6® |
|
Portfolio antibodies |
|
|
| Biotecnol S.A. |
|
Dec. 2006 |
|
PER.C6® |
|
Portfolio antibodies |
|
|
| Novartis |
|
Sep. 2006 |
|
STAR® |
|
Proteins, portfolio antibodies |
|
|
| UCB S.A. |
|
Sep. 2006 |
|
STAR® |
|
Monoclonal antibodies |
|
|
| MorphoSys A.G. |
|
Aug. 2006 |
|
PER.C6® |
|
Inflammatory diseases |
|
|
|
UMN Pharma |
|
Mar. 2006 |
|
PER.C6® |
|
Undisclosed protein |
|
|
|
Ferring International Research Center S.A. |
|
Dec. 2005 |
|
PER.C6® |
|
Women’s healthcare |
|
|
|
IQ Corp. |
|
Oct. 2005 |
|
PER.C6® |
|
Anti-anthrax antibody |
|
|
|
Ferring International Research Center SA |
|
May 2005 |
|
PER.C6® |
|
Women’s healthcare |
|
|
|
Micromet A.G. |
|
Nov. 2004 |
|
PER.C6® |
|
Portfolio antibodies |
|
|
|
MorphoSys A.G. |
|
Aug. 2004 |
|
PER.C6® |
|
Portfolio antibodies |
|
|
|
Novartis Vaccines and Diagnostics |
|
Jun. 2004 |
|
PER.C6® |
|
Portfolio antibodies |
|
|
|
Merus B.V. |
|
Jun. 2004 |
|
PER.C6® |
|
Portfolio oligoclonics |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Elm Biotech Pty Ltd. |
|
Dec. 2008 |
|
PER.C6® |
|
Adenovirus-vectored product |
|
|
|
Vascular Biogenics Ltd |
|
Mar. 2005 |
|
PER.C6® |
|
Portfolio |
|
|
|
NeoTropix |
|
Mar. 2004 |
|
PER.C6® |
|
Oncology |
|
|
|
TapImmune |
|
Aug. 2003 |
|
PER.C6® |
|
Portfolio |
|
|
|
Transgene SA |
|
April 2001 |
|
PER.C6® |
|
Portfolio |
|
|
|
Ark Therapeutics |
|
Nov. 2000 |
|
PER.C6® |
|
Portfolio |
|
|
|
Merck & Co., Inc. |
|
Nov. 1998 |
|
PER.C6® |
|
Portfolio |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lonza |
|
Nov. 2008 |
|
PERMEXCIS™ |
|
Medium development |
|
Biochrom |
|
Nov. 2008 |
|
PERMEXCIS™ |
|
Medium development |
|
Cambrex |
|
Aug. 2004 |
|
PER.C6® |
|
Medium development |
| JRH Biosciences Inc. |
|
May 2004 |
|
PER.C6® |
|
Medium development Recombinant vaccines |
|
Sigma-Aldrich Corp. |
|
Dec. 2003 |
|
PER.C6® |
|
Medium development |
|
Hyclone, Inc. |
|
Dec. 2003 |
|
PER.C6® |
|
Medium development |
|
Invitrogen Corp. |
|
June 2003 |
|
PER.C6® |
|
Medium development |
|
DSM Biologics |
|
Dec. 2002 |
|
PER.C6® |
|
Therapeutic proteins (including antibodies) |
|
Molecular Medicine BioServices, Inc. |
|
Dec. 2001 |
|
PER.C6® |
|
Recombinant vaccines & gene therapy products (USA) |
|
|
|
|
|
|
|
|
|
|
|
|
Galapagos Genomics N.V. |
|
June 1999 |
|
PER.C6® |
|
Genomics |
|
|
|
About Us
